<< Read Full Article
<< Read Full Article
The Biotech Stock Mailbag is open.
Erik D.M. writes, "Hey mister journalist, still feeling the same about Hemispherx Biopharma(HEB Quote) as you did a couple of days ago? I don't see you writing anything negative anymore, or did you buy them yourself, too?"
Nope, I still feel the same way about Ampligen -- a long shot for U.S. Food and Drug Administration approval as a treatment for chronic fatigue syndrome. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,501.05 | 1,114.11 | 2,212.10 | 35.46 |
Oil *
71.84
|
|
UP
29.55
|
UP
7.70
|
UP
21.79
|
UP
0.06
|
10 Yr
3.55%
SPDR Gold
110.24
|
|
+0.28%
|
+0.70%
|
+0.99%
|
+0.17%
|
Data delayed 20 minutes |
Connect with TheStreet